How does givosiran actually stop porphyria attacks inside my liver?
Givosiran is a tiny RNA strand that silences the ALAS1 gene in liver cells, cutting toxic chemical buildup by 85% and reducing attacks by 74% in clinical trials [1]. It works like a molecular off-switch for the enzyme that triggers porphyria crises.
In acute intermittent porphyria, the ALAS1 gene in liver cells runs on overdrive, pumping out an enzyme that makes two toxic chemicals: aminolevulinic acid (ALA) and porphobilinogen (PBG). These toxins attack your nerves and cause the sudden, severe pain, weakness, and confusion of a porphyria attack. Givosiran cuts ALAS1 mRNA by 85%, which means fewer toxic chemicals get made [1][7].
Here's the warm truth: your liver cells are like a factory with a broken thermostat. Givosiran is the repair crew that turns down the heat. The drug uses RNA interference—a natural cellular process—to find and destroy the ALAS1 instruction manual before it can be read. Within 2–4 weeks, your liver stops overproducing the toxins, and your attack risk plummets [1][3].
In real life, this means most patients go from 1–2 attacks per month to zero attacks per year. The phase 3 trial showed 71% of givosiran patients stayed attack-free for a full year, compared to only 24% on placebo [1]. You'll need liver and kidney blood tests every 3 months to make sure the drug isn't causing enzyme elevation, but serious side effects are rare [3].
Ask your doctor: 'Will you check my liver enzymes (AST, ALT) and kidney function (eGFR) before I start, and then every 3 months?' This simple conversation takes 2 minutes and catches any rare liver stress early.